

## CE Mark for CT:VQ™ and \$83M placement to fund European expansion

27 March 2026

### Highlights

- CT:VQ™, the world's first and only non-contrast, CT-based ventilation-perfusion imaging technology, receives CE Mark certification, enabling commercial deployment across the European Union (EU), one of the world's largest respiratory imaging markets
- Simultaneously, 4DMedical completes an \$83 million private placement at \$5.90 per share, following significant inbound interest from institutions looking to invest in the Company
- Proceeds will be used to fund the expansion and acceleration of CT:VQ™ into the EU, while maintaining balance sheet strength
- The placement price of \$5.90 represents a 6.1% discount to the last close and a 12.3% premium to the 5-day VWAP
- The placement represents an increase of 2.45% in shares on issue
- With CT:VQ™ now deployed at six leading U.S. Academic Medical Centers, the combination of CE Mark and the \$83 million placement provides the platform to replicate that success across the EU
- Strong proforma cash balance of \$289 million as at 31 December 2025

**Melbourne, Australia, 27 March 2026** – 4DMedical Limited (ASX: 4DX, “4DMedical” or the “Company”), a global leader in respiratory imaging technology, today announces that CT:VQ™ has received CE Mark certification for commercial use in the European Union. Coincident with this regulatory milestone, the Company has received total firm commitments from select institutional investors for an \$83 million single-tranche private placement at an issue price of \$5.90 per share.

CT:VQ™ is the world's first and only non-contrast, CT-based ventilation-perfusion imaging solution. CE Mark certification opens the door to immediate commercial engagement with healthcare providers across the European Union, paving the way for clinical adoption and collaboration with major European hospital networks.

### Regulatory clearance – product portfolio

|                     | Product                       | Regulatory Clearance                                 |        |        |           |
|---------------------|-------------------------------|------------------------------------------------------|--------|--------|-----------|
|                     |                               | US                                                   | Canada | Europe | Australia |
| Pulmonary Function  | XV LVAS®                      | Dynamic Ventilation Analysis (Fluoroscopy)           | ✓      |        | ✓         |
|                     | CT LVAS™                      | CT-based Ventilation Analysis                        | ✓      |        | ✓         |
|                     | CT:VQ™                        | Ventilation + Perfusion from routine non contrast CT | ✓      | ✓      |           |
|                     | Functional LDA (LDAf)         | Air Trapping + Emphysema                             | ✓      | ✓      | ✓         |
| Pulmonary Structure | Lung Density Analysis™ (LDAi) | Emphysema, HAA, Fissures                             | ✓      | ✓      | ✓         |
|                     | Lung Texture Analysis™ (LTA)  | ILD's / Fibrosis                                     | ✓      | ✓      | ✓         |
|                     | IQ-UIP™                       | IPF Screening for UIP pattern                        | ✓      |        |           |
|                     | Lung Nodules                  | Lung Cancer (Partner Solution)                       | ✓      | ✓      | ✓         |
| Cardio-vascular     | CAC™                          | Coronary Calcification/Heart Disease                 | ✓      | ✓      |           |
|                     | PHA™                          | Pulmonary Hypertension (RV/LV, Pa/Ao)                | ✓      |        |           |
|                     | RVLV™                         | Pulmonary Hypertension (RV/LV)                       | ✓      | ✓      | ✓         |

4DMedical Limited (ASX:4DX) 2026

**The future of  
lung health**

**Melbourne**  
 Level 7 Melbourne Connect  
 700 Swanston Street  
 Carlton VIC 3053  
 Tel: +61 (3) 9545 5940

**Los Angeles**  
 21255 Burbank Boulevard  
 Suite 120  
 Woodland Hills CA 91367  
 Tel: +1 (818) 403-8490

4DMedical Limited  
 ABN: 31 161 684 831  
 Email: [info@4DMedical.com](mailto:info@4DMedical.com)  
[www.4DMedical.com](http://www.4DMedical.com)



### CE Mark certification unlocks major European market opportunity

The European Union represents a significant commercial opportunity for CT:VQ™. With a population exceeding 450 million, and a highly developed hospital-based imaging infrastructure, the EU constitutes one of the largest global markets for advanced cardiothoracic imaging.

CT is the dominant diagnostic imaging modality across European healthcare systems, supported by an extensive network of CT scanners and well-established clinical workflows. Ventilation-perfusion (VQ) imaging is routinely used for the investigation of pulmonary embolism and other cardiopulmonary conditions in the EU, yet access to nuclear VQ imaging remains constrained in many regions due to radiotracer availability, workforce limitations, and operational complexity.

CT:VQ™ directly addresses these challenges by delivering quantitative ventilation-perfusion insights from routine non-contrast CT scans, without the need for radiotracers or specialised infrastructure. CE Mark certification enables 4DMedical to immediately engage with key healthcare providers across the EU, supporting clinical adoption, commercial rollout, and collaboration with leading respiratory centres.

Beyond the direct commercial opportunity, Europe plays a critical role in shaping global clinical practice in respiratory imaging. Many of the world's leading respiratory thought leaders, academic centres, and international congresses are based in Europe, and regulatory clearance materially enhances 4DMedical's ability to engage with these clinicians, support locally led research, and contribute to the global evidence base for CT:VQ™. In parallel, investment in Europe will increase visibility among U.S. clinicians, many of whom regularly attend European congresses and collaborate closely with European research groups.

### Private placement to fund European expansion

The private placement to raise \$83 million was completed at an issue price of \$5.90 per share. The issue price represents a 6.1% discount to the last closing price on 26 March 2026 and a 12.3% premium to the 5-day VWAP.

Proceeds will fund the commercial launch of CT:VQ™ across Europe and international markets, support clinical integration for new customers, and strengthen the balance sheet to pursue strategic growth opportunities, including potential acquisitions.

The placement will result in the issue of approximately 14.1 million shares at \$5.90 per share ("**Placement Shares**") within the Company's existing placement capacity under ASX Listing Rule 7.1, representing an increase of approximately 2.45% in shares on issue.

Settlement of the placement is expected to occur on 1 April 2026, with the Placement Shares expected to be allotted and to commence trading on 2 April 2026.

Bell Potter Securities Limited acted as Lead Manager and Bookrunner to the private placement.

### 4DMedical MD/CEO and Founder Andreas Fouras said:

*CE Mark certification for CT:VQ™ is a significant milestone that opens access to one of the world's largest and most sophisticated healthcare markets. Combined with FDA clearance, 4DMedical now holds regulatory approval to rapidly commercialise CT:VQ™ across both the U.S. and the EU.*

*Since FDA clearance, rapid adoption by leading U.S. institutions including Stanford, Cleveland Clinic, University of Miami, UC San Diego Health, the University of Chicago Medicine and, most recently, Mayo Clinic reflects the level of excitement CT:VQ™ is generating in the United States. This placement, timed alongside CE Mark certification, gives us the resources to carry that same momentum into Europe.*



*The clinical need for CT:VQ™ is universal. The limitations of nuclear VQ scanning - radiotracer constraints, limited access, operational complexity - exist in every healthcare system. With an estimated 400,000 nuclear VQ scans performed annually across the EU, and an extensive network of CT scanners, the European opportunity is substantial and immediate.*

*We are already developing exciting plans to deploy this capital in Europe, and we look forward to sharing those plans with you before the end of FY26.*

**–ENDS–**

Authorised by the 4DMedical Board of Directors.

## Contacts

### Corporate

Investor Relations

[investor.relations@4dmedical.com](mailto:investor.relations@4dmedical.com)

### Administration

Company Secretary

[companysecretary@4dmedical.com](mailto:companysecretary@4dmedical.com)

### Media Enquiries

Julia Maguire

[julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)

## About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company revolutionising respiratory care with advanced imaging and artificial intelligence. Its patented **XV Technology®** transforms standard scans into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision.

4DMedical's expanding software portfolio includes the FDA-cleared **XV Lung Ventilation Analysis Software (XV LVAS®)**, **CT LVAS™**, and the ground-breaking **CT:VQ™** solution designed to set new benchmarks in cardiothoracic imaging by combining ventilation and perfusion analysis.

Delivered seamlessly through a Software-as-a-Service (SaaS) model, 4DMedical's solutions integrate into existing hospital infrastructure, enhancing physician productivity and enabling more personalised patient care. With the addition of advanced AI capabilities from its 2023 acquisition of **Imbio**, 4DMedical continues to push the boundaries of medical imaging to redefine how respiratory disease is understood and treated worldwide.

Learn more at [www.4dmedical.com](http://www.4dmedical.com)